MedTrace Logo

Biomarker Study of Pancreatic Neuroendocrine Tumours

NCT03741517 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-05-18

No results posted yet for this study

Summary

The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor hormone secretion. This study aims to characterize how the biology of pancreatic neuroendocrine tumors change over time, measured by; patient symptoms, biochemistry, contrast enhanced computed tomography, DOTATOC-PET, FDG-PET and core needle biopsy with histopathological analysis (Ki67 index and tumor cell differentiation). Uptake on 68Ga-DOTATOC and 18F-FDG-PET will be correlated directly to tumor cell proliferation rate. Fraction of patients with spatial heterogeneity in DOTATOC as well as FDG uptake as well as metachronous changes in all collected data will be documented. Biomaterial from whole blood and core needle biopsies will be characterized on the molecular level, and those findings will be integrated to the above specified clinical parameters.

Conditions

  • Pancreatic Neuroendocrine Tumor

Interventions

RADIATION

18F-FDG-PET

Fludeoxyglucose F18

RADIATION

68Ga-DOTATOC-PET

DOTA-tyr3-Octreotide Ga68

RADIATION

Computed tomography

Computed tomography of thorax and abdomen with 3-phase contrast

OTHER

Core needle biopsy

Core needle biopsy of metastatic lesions

OTHER

Phlebotomy

Phlebotomy from peripheral vein

Sponsors & Collaborators

  • Uppsala University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-30
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03741517 on ClinicalTrials.gov